BACKGROUND:
METHODS:
Samples were collected from 32 patients (23
girls and 9 boys) fulfilling the ILAR criteria for
JIA (19 oligoarthritis, 13 polyarthritis) with a
median age of 7,98 yrs. The groups were
further subdivided according to time of
diagnosis and course of disease. MRP 8/14 was
measured by Bhlmann MRP8/14 Calprotectin
ELISA kit (Bhlmann Laboratories, Switzerland).
CRP and ESR were measured as part of routine
clinical assessment. The levels of IL-6 were
measured using immunoturbidimetric assay.
Parametric tests were used for analyses.
Newly diagnosed
Poor response/
Disease flare
6
4
2
Oligoarthritis
n=6
Poor response/
Disease flare
25
n=7
n=12
n=7
Newly diagnosed
40
35
RESULTS:
High serum level of MRP8/14 was observed in
23 (65.7%) of the 32 children with JIA. The
levels of MRP8/14 were significantly higher in
the polyarthritis group compared to the
oligoarthritis (p<0,05). Similarly, the levels of
CRP and IL-6 were significantly higher in
polyarthritis (p<0,05).
70
50
60
50
40
30
20
30
20
15
10
5
0
Oligoarthritis Polyarthritis
60
40
30
Oligoarthritis Polyarthritis
IL-6 (pg/ml)
CRP (mg/l)
ESR (mm/h)
45
Polyarthritis
20
10
10
0
Oligoarthritis Polyarthritis
Oligoarthritis Polyarthritis
CONCLUSION:
Highest levels of MRP8/14 were detected in the
polyarthritis group which corresponds with the
poorer prognosis of this group. A good
correlation between concentrations of MRP8/14
and CRP was observed. A longitudinal follow-up
of MRP8/14 serum levels is needed in order to
monitor the disease activity, identify patients
with higher risk for relapse, and response to
treatment in individual patients.